Literature DB >> 17532527

Orphan nuclear receptors in drug discovery.

Yanhong Shi1.   

Abstract

Orphan nuclear receptors provide a unique resource for uncovering novel regulatory systems that impact human health and also provide drug targets for a variety of human diseases. Ligands of nuclear receptors have been used in several important therapeutic areas, such as breast cancers, skin disorders and diabetes. Orphan nuclear receptors, therefore, represent a tremendous opportunity in understanding and treating human diseases. Here, I highlight recent advances in the use of orphan nuclear receptors and their potential as targets for drug discovery in diabetes, obesity, neurodegenerative diseases and other related disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532527      PMCID: PMC2748783          DOI: 10.1016/j.drudis.2007.04.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  69 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  Rational discovery of novel nuclear hormone receptor antagonists.

Authors:  M Schapira; B M Raaka; H H Samuels; R Abagyan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

4.  PPAR gamma is required for placental, cardiac, and adipose tissue development.

Authors:  Y Barak; M C Nelson; E S Ong; Y Z Jones; P Ruiz-Lozano; K R Chien; A Koder; R M Evans
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

5.  Requirement for RORgamma in thymocyte survival and lymphoid organ development.

Authors:  Z Sun; D Unutmaz; Y R Zou; M J Sunshine; A Pierani; S Brenner-Morton; R E Mebius; D R Littman
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

6.  The orphan nuclear receptor Tlx regulates Pax2 and is essential for vision.

Authors:  R T Yu; M Y Chiang; T Tanabe; M Kobayashi; K Yasuda; R M Evans; K Umesono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 7.  Identification of a potent agonist of the orphan nuclear receptor Nurr1.

Authors:  Celine Dubois; Bastian Hengerer; Henri Mattes
Journal:  ChemMedChem       Date:  2006-09       Impact factor: 3.466

8.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.

Authors:  N Kubota; Y Terauchi; H Miki; H Tamemoto; T Yamauchi; K Komeda; S Satoh; R Nakano; C Ishii; T Sugiyama; K Eto; Y Tsubamoto; A Okuno; K Murakami; H Sekihara; G Hasegawa; M Naito; Y Toyoshima; S Tanaka; K Shiota; T Kitamura; T Fujita; O Ezaki; S Aizawa; T Kadowaki
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

9.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

Authors:  S Rocchi; F Picard; J Vamecq; L Gelman; N Potier; D Zeyer; L Dubuquoy; P Bac; M F Champy; K D Plunket; L M Leesnitzer; S G Blanchard; P Desreumaux; D Moras; J P Renaud; J Auwerx
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

10.  Activation of PPARdelta alters lipid metabolism in db/db mice.

Authors:  M D Leibowitz; C Fiévet; N Hennuyer; J Peinado-Onsurbe; H Duez; J Bergera; C A Cullinan; C P Sparrow; J Baffic; G D Berger; C Santini; R W Marquis; R L Tolman; R G Smith; D E Moller; J Auwerx
Journal:  FEBS Lett       Date:  2000-05-19       Impact factor: 4.124

View more
  26 in total

1.  Structure-dependent activation of NR4A2 (Nurr1) by 1,1-bis(3'-indolyl)-1-(aromatic)methane analogs in pancreatic cancer cells.

Authors:  Xi Li; Syng-Ook Lee; Stephen Safe
Journal:  Biochem Pharmacol       Date:  2012-03-03       Impact factor: 5.858

Review 2.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Seeing the future of bioactive lipid drug targets.

Authors:  Jilly F Evans; John H Hutchinson
Journal:  Nat Chem Biol       Date:  2010-07       Impact factor: 15.040

4.  Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment.

Authors:  Mohammad Jodeiri Farshbaf; Mahboobeh Forouzanfar; Kamran Ghaedi; Abbas Kiani-Esfahani; Maryam Peymani; Alireza Shoaraye Nejati; Tayebeh Izadi; Khadijeh Karbalaie; Maryam Noorbakhshnia; Soheila Rahgozar; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

Review 5.  Minireview: the role of nuclear receptors in photoreceptor differentiation and disease.

Authors:  Douglas Forrest; Anand Swaroop
Journal:  Mol Endocrinol       Date:  2012-05-03

Review 6.  Orphan Nuclear Receptors in Colorectal Cancer.

Authors:  Michael E Kelly; Helen M Mohan; Alan W Baird; Elizabeth J Ryan; Des C Winter
Journal:  Pathol Oncol Res       Date:  2018-06-28       Impact factor: 3.201

Review 7.  Targeting NR4A1 (TR3) in cancer cells and tumors.

Authors:  Syng-Ook Lee; Xi Li; Shaheen Khan; Stephen Safe
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

8.  Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.

Authors:  Sophia Sn Lam; Abby Sc Mak; Judy Wp Yam; Annie Ny Cheung; Hextan Ys Ngan; Alice St Wong
Journal:  Mol Ther       Date:  2014-01-14       Impact factor: 11.454

Review 9.  A complex task? Direct modulation of transcription factors with small molecules.

Authors:  Angela N Koehler
Journal:  Curr Opin Chem Biol       Date:  2010-04-13       Impact factor: 8.822

Review 10.  Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Authors:  Stephen Safe; Un-Ho Jin; Erik Hedrick; Alexandra Reeder; Syng-Ook Lee
Journal:  Mol Endocrinol       Date:  2013-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.